The Journal of Neuroscience, October 3, 2007, 27(40):10810-10817; doi:10.1523/JNEUROSCI.3269-07.2007
Previous Article | Next Article 
Neurobiology of Disease
Paradoxical Upregulation of Glutamatergic Presynaptic Boutons during Mild Cognitive Impairment
Karen F. S. Bell,1
David A. Bennett,4 and
A. Claudio Cuello1,2,3
Departments of 1Pharmacology and Therapeutics, 2Anatomy and Cell Biology, and 3Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada H3G 1Y6, and 4Rush Alzheimer's Disease Center, Armour Academic Center, Chicago, Illinois 60612
Correspondence should be addressed to Dr. A. Claudio Cuello, Room 1210, 3655 Sir William Osler Promenade, Montreal, Quebec, Canada H3G 1Y6. Email: claudio.cuello{at}mcgill.ca
Synaptic integrity is now recognized as a central component of Alzheimer's disease. Surprisingly, however, the structural status of glutamatergic synapses in Alzheimer's disease is unclear, despite the fact that glutamate is the major excitatory transmitter of the CNS and has key roles in excitotoxicity and long-term potentiation. The identification of specific markers of glutamatergic neurons now allows an assessment of the structural involvement of the glutamatergic system across progressive stages of the Alzheimer's pathology, an opportunity not afforded by previously used neurochemical approaches. Glutamatergic presynaptic bouton density and dystrophic neurite abundance were quantified in midfrontal gyrus brain tissue from subjects with no cognitive impairment, mild cognitive impairment, or mild- or severe-stage Alzheimer's disease. Our study demonstrates a striking pathology-dependent pattern of glutamatergic synaptic remodeling with disease progression. Subjects with mild cognitive impairment display a paradoxical elevation in glutamatergic presynaptic bouton density, a situation akin to that observed in the cholinergic system, which then depletes and drops with disease progression. This pattern of synaptic remodeling mirrors our previous findings in transgenic animal models and is of major relevance to current transmitter-based therapeutics.
Key words: Alzheimer's disease; mild cognitive impairment; glutamatergic; presynaptic bouton; dystrophic neurite; MMSE
Received March 21, 2007;
revised Aug. 21, 2007;
accepted Aug. 24, 2007.
Correspondence should be addressed to Dr. A. Claudio Cuello, Room 1210, 3655 Sir William Osler Promenade, Montreal, Quebec, Canada H3G 1Y6. Email: claudio.cuello{at}mcgill.ca